Cathie Wood's ARK Invest is actively rebalancing its healthcare portfolio, significantly reducing its stake in Twist Bioscience while increasing investments in Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte. This strategic shift indicates a rotation towards companies with more immediate clinical and diagnostic catalysts within the genomics sector.
Cathie Wood's ARK Invest is undertaking a notable rebalancing within its healthcare ETFs, particularly ARKK and ARKG. The most significant action is the continued and heavy selling of Twist Bioscience (TWST), marking the 21st consecutive session, indicating a loss of conviction or a strategic reallocation away from the company despite its AI-enabled drug discovery exposure. Conversely, ARK is aggressively buying into Recursion Pharmaceuticals (RXRX), Intellia Therapeutics (NTLA), and Veracyte (VCYT). This shift suggests a preference for companies with more tangible, near-term catalysts, such as Intellia's impending FDA decision for its CRISPR therapy and Veracyte's strong revenue growth and strategic acquisitions. For traders, this signals a potential bearish sentiment for TWST in the short term due to sustained institutional selling pressure, while RXRX, NTLA, and VCYT could see increased investor interest and positive momentum from ARK's continued accumulation, especially given NTLA's regulatory milestone.